47 results about "De differentiation" patented technology

Systems and compositions comprising zotarolimus that are safer, more effective and produce less inflammation than rapamycin and paclitaxel systems are disclosed. Medical devices comprising supporting structures capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient can contain one or more therapeutic agents or substances, with the carrier including a coating on the surface thereof, and the coating having the therapeutic compounds, including, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs.

A medical device comprising a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to,

This drug can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs.

Methods of de-differentiating somatic cells to an embryonic stem cell state comprising direct delivery of a protein into the somatic cell, wherein the protein effects de-differentiation of the somatic cell to an embryonic stem cell phenotype.

A system and compositions including zotarolimus and paclitaxel are disclosed, as well as methods of delivery, wherein the drugs have effects that complement each other. Medical devices are disclosed which include supporting structures that include at least one pharmaceutically acceptable carrier or excipient, which carrier or excipient can include one or more therapeutic agents or substances, with the carrier including at least one coating on the surface thereof, and the coating associated with the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs.

Systems and compositions comprising paclitaxel and a second drug, such as rapamycin, analogs, derivatives, salts and esters thereof are disclosed, as well as methods of delivery wherein the drugs have effects that complement each other. Medical devices comprising supporting structures capable of including or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient can contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating including the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs.

A system and compositions including zotarolimus and paclitaxel are disclosed, as well as methods of delivery, wherein the drugs have effects that complement each other. Medical devices are disclosed which include supporting structures that include at least one pharmaceutically acceptable carrier or excipient, which carrier or excipient can include one or more therapeutic agents or substances, with the carrier including at least one coating on the surface thereof, and the coating associated with the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs.

The invention belongs to a flower and plant propagation method and particularly relates an asexual rapid propagation method for flowers and plants. In the asexual rapid propagation method, infant flower base parts of ornithogalum caudatum infant inflorescences are taken as explants for carrying out tissue culture; the de-differentiation rate and the differentiation rate can be up to more than 75%. A callus which is induced by one explant can be subjected to repeated subculture so as to differentiate about 500 cluster buds; the phenotypes of the cluster buds are uniform. The rooting rate of the cluster buds can be up to more than 90% and the transplanting survival rate under a suitable environment is up to 100%. The ornithogalum caudatum can be propagated into plants with completely same genetic backgrounds and ordered appearances in a large scale within a relative short time; the variation of regenerated plants is low; a regeneration system is very efficient; the cost of an average single-plant regenerated seedling is very low; the asexual rapid propagation method is suitable for being used in large-batch, efficient and rapid propagation of the ornithogalum caudatum and is very suitable for being used in industrial production.

An apparatus that provides synchronized chronic electrical stimulation and chronic stretch to a cell culture or tissue. The apparatus includes a programmable controller which synchronizes stretch and electrical stimulation applied to a deformable culture container, such as a silicone rubber culture dish. The apparatus is used to treat cells and retard de-differentiation or promote differentiation and maturation in some applications.

A system and compositions including zotarolimus and paclitaxel are disclosed, as well as methods of delivery, wherein the drugs have effects that complement each other. Medical devices are disclosed which include supporting structures that include at least one pharmaceutically acceptable carrier or excipient, which carrier or excipient can include one or more therapeutic agents or substances, with the carrier including at least one coating on the surface thereof, and the coating associated with the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs.

The invention provides a method of effecting de-differentiation of an at least partially differentiated cell or of maintaining pluripotency and/or self-renewing characteristics of an undifferentiated cell. The method comprises increasing the amount or the activity of an Err protein, or a functional fragment thereof, in the cell.

The invention discloses an anti-Doppler frequency shift synchronization method based on pseudo-random sequence differential coding. The anti-Doppler frequency shift synchronization method can simultaneously realize time and bit timing synchronization in the case of strong Doppler frequency shift, is suitable for a single/multi-carrier system, and comprises the steps of: (1) performing differentialencoding on a pseudo-random sequence at a transmitting end, regarding the pseudo-random sequence after differential encoding as pilots, and maintaining autocorrelation property thereof; (2) performing de-differentiation processing on two orthogonal sampling signals before sliding correlation detection of the receiving end; (3) realizing correlation operation of received signals and local pilot symbols by means of filtering, comparing a correlation peak value output by a filter with a set threshold, and further determining a time synchronization moment; (4) and comparing a signal sequence extracted from different clock skew with a correlation peak of the local pilot, determining the optimal extraction clock, and realizing bit timing synchronization. The anti-Doppler frequency shift synchronization method adopts interceptive m sequences, suppresses the influence of Doppler frequency shift on synchronization through differential encoding, and can apply the pilot sequence to frequency offset and channel estimation, thereby laying a foundation for the subsequent frequency offset compensation and demodulation processing.

A method for the identification of a composition useful in the treatment of an overweight or obese person to reduce the person's body mass index is provided which comprises obtaining an extract of an ethnobotanical plant, and evaluating the activity of the extract in an assay selected from the group consisting of a lipolysis assay, an assay that measures the amount of glycerol introduced by a cell into a suspension medium of the cell, an adipocyte differentiation assay, an assay that measures the level of the enzyme glycerol-3-phosphate dehydrogenase, an assay that measures the inhibition of differentiation of preadipocytes to adipocytes, an assay that measures the accumulation of lipid in an adipocyte, an assay that measures the de-differentiation of adipocytes into preadipocytes, and combinations thereof. Sclareol and sclareol-like compounds and sclareolide and sclareolide-like compounds are identified as useful in the treatment of overweight and obese conditions and disorders and conditions associated with adipose tissue abnormalities. These compounds can be formulated for oral administration.

The invention discloses a method for efficiently acquiring a gerbera jamesonii detoxification seedling. The method is characterized by comprising the following steps: (1) collecting gerbera jamesonii tender leaves, and de-differentiating the gerbera jamesonii to generate callus; (2) thermally treating the callus, continuously inducing the callus to form adventitious bud, and rooting the adventitious bud to form a strong tissue culture seedling; (3) further stripping a tissue culture seedling stem tip, and de-differentiating to generate callus; (4) thermally treating the callus, and inducing to form a seedling; (5) randomly extracting the tissue culture seedling in the step (4), carrying out the virus detection, if the seedling is qualified in detection, the seedling is the gerbera jamesonmii detoxification seedling, if the seedling is not qualified in the detection, repeating the steps (1) to (4) until the qualified gerbera jamesonii detoxification seedling is acquired. The callus is generated by virtue of the twice de-differentiation, and then the callus is thermally treated and de-differentiated to finally obtain the gerbera jamesonii detoxification seedling, so that the difficulty of the existing detoxification technology such as non-thoroughness in detoxification, complexity in operation and can meet the factory-like detoxification production requirement.

Available evidence indicates that tumor cells exhibit consistent abnormalities in Calcium influx and intracellular storage of sequestered Calcium when compared to normal cells. The present invention provides clinical methods by which such differences are exploited to induce Apoptosis selectively in tumor cells while sparing normal cells. These methods are based upon employing drugs that, acting alone or in synergistic combinations, produce an increase in intracellular Calcium loading such that either or both of two major Apoptotic pathways are triggered to produce selective killing of malignant cells. Since the invention is based upon fundamental cell cycle requirements, to the extent that Calcium handling abnormalities are a general characteristic of the malignant state, the methods presented here are widely applicable regardless of tissue of origin and degree of cellular de-differentiation.